1111 GMT - Sanofi will provide little commentary about strategic priorities at its first-quarter results later this month since new CEO Belen Garijo won't start until shortly afterward, UBS analysts say in a research note. The French drugmaker's results are likely to be positive, but any strategic update will be limited, the analysts say. "Prior management comments suggested the potential for a refocus on the Regeneron [joint venture] for future drug launches but we assume it is too early to explore this potential." Recent drug-pipeline disappointments have made many investors lukewarm on Sanofi, but its steady growth in the near and medium term might attract some, UBS says. Shares rise 0.3%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 10, 2026 07:12 ET (11:12 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.